Immuneering Corp (IMRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 150K 300K 450K FY22: 317K FY23: 0 FY22 FY23

Gross Profit Annual

0 60K 120K 180K FY22: 158.8K FY23: 0 FY22 FY23

Operating Income Annual

-75M -50M -25M 0 25M 50M 75M FY24: -64.1M FY25: -59.4M FY24 FY25

Net Income Annual

-75M -50M -25M 0 25M 50M 75M FY24: -61M FY25: -56M FY24 FY25

Cost of Revenue Annual

0 60K 120K 180K FY22: 158.1K FY23: 0 FY22 FY23

Operating Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M FY24: -55M FY25: -45.3M FY24 FY25

Free Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M FY24: -55.1M FY25: -45.5M FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 15M 30M 45M FY24: 30M FY25: 44M FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.10 -1.40 -0.70 0.00 0.70 1.40 2.10 Q3 '24: -1.97 Q4 '24: -2.04 Q1 '25: -1.97 Q2 '25: -1.90 Q3 '25: -1.79 Q4 '25: -1.27 Q1 '26: -1.06 Q2 '26: -0.93 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.